布瓦西坦、西诺氨酯、拉考沙胺与吡仑帕奈治疗局灶性癫痫的比较效果
该多中心 pooled 分析纳入 1949 例耐药性局灶性癫痫成人患者,比较四种新型抗癫痫发作药物作为添加治疗的效果与安全性。结果显示,西诺氨酯在 6 个月和 12 个月应答率及癫痫无发作方面优于布瓦西坦、拉考沙胺和吡仑帕奈,但不良事件发生率最高。
要点
- 西诺氨酯 6 个月应答率显著优于布瓦西坦、吡仑帕奈和拉考沙胺。
- 西诺氨酯 12 个月保留率高于布瓦西坦和吡仑帕奈,与拉考沙胺无显著差异。
- 西诺氨酯不良事件发生率最高(57.8%),拉考沙胺最低(14.8%)。
核心结论
- 在耐药性局灶性癫痫成人患者中,西诺氨酯作为添加治疗的效果优于布瓦西坦、拉考沙胺和吡仑帕奈。
研究设计与样本
- 多中心 pooled 分析,汇总 4 项既往回顾性真实世界病历回顾研究(2017 年 1 月至 2024 年 1 月)。
- 纳入 1949 例耐药性局灶性癫痫成人患者(年龄≥16 岁),来自 71 个癫痫中心,共分析 1993 条抗癫痫发作药物处方。
主要发现
- 12 个月时,西诺氨酯在应答率和癫痫无发作方面持续优于其他药物。
- 西诺氨酯随访期间不良事件发生率最高(57.8%),拉考沙胺最低(14.8%)。
临床怎么用
- 对于耐药性局灶性癫痫成人患者,西诺氨酯可作为添加治疗的有效选择,但需关注其较高的不良事件风险。
- 选择药物时需权衡疗效与耐受性,拉考沙胺不良事件发生率较低。
局限性
- 本研究为回顾性真实世界研究,可能存在选择偏倚和混杂因素。
- 西诺氨酯处方比例较低(9.6%),可能影响结果的外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Treatment decisions in drug-resistant focal epilepsy remain largely empirical, as direct comparative evidence among newer antiseizure medications (ASMs) is limited. Real-world data can complement randomized clinical trials by providing insights into long-term effectiveness and safety across diverse populations. OBJECTIVE: To compare effectiveness and safety of brivaracetam, cenobamate, lacosamide, and perampanel as adjunctive therapies in adults with drug-resistant focal epilepsy. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter pooled analysis of 4 previously conducted retrospective real-world medical record-review studies (January 2017-January 2024). Included were adult patients (aged ≥16 years) with drug-resistant focal epilepsy, as defined by the International League Against Epilepsy. Participants were recruited from 71 epilepsy centers. EXPOSURES: Add-on treatment with brivaracetam, cenobamate, lacosamide, or perampanel. MAIN OUTCOMES AND MEASURES: The primary outcome was the responder rate at 6 months, defined as greater than or equal to 50% seizure frequency reduction from baseline. Secondary outcomes included 12-month responder rate, seizure freedom (≥3 months at 6 months and ≥6 months at 12 months), and 12-month ASM retention. Safety was assessed by incidence of adverse effects. Generalized linear mixed models adjusted for demographic and clinical covariates were used to compare treatment outcomes, with cenobamate as reference ASM. RESULTS: Of 2386 ASM prescriptions screened, 1993 prescriptions from 1949 patients (1036 of 1947 female [53.2%]; sex information was missing in 0.1% of prescriptions) with a median (IQR) age of 42 (29-55) years at ASM prescription, met inclusion criteria and were included in the pooled analysis. Brivaracetam accounted for 953 prescriptions (47.8%), followed by perampanel (607 [30.5%]), lacosamide (241 [12.1%]), and cenobamate (192 [9.6%]). After adjustment, cenobamate demonstrated significantly higher odds of 50% or greater response at 6 months compared with brivaracetam (odds ratio [OR], 0.18; 95% CI, 0.12-0.28; P < .001), perampanel (OR, 0.26; 95% CI, 0.16-0.42; P < .001), and lacosamide (OR, 0.29; 95% CI, 0.17-0.49; P < .001). Results were consistent for secondary effectiveness outcomes at 12 months, with cenobamate outperforming other ASMs in terms of 50% or greater response and seizure freedom. Cenobamate was associated with the highest rate of adverse effects during follow-up (111 [57.8%]), and lacosamide was associated with the lowest (35 [14.8%]). Cenobamate was associated with a higher likelihood of treatment retention at 12 months compared with brivaracetam (OR, 0.43; 95% CI, 0.26-0.69; P < .001) and perampanel (OR, 0.56; 95% CI, 0.32-0.99; P = .047), with no significant difference vs lacosamide (OR, 0.81; 95% CI, 0.41-1.59; P = .53). CONCLUSIONS AND RELEVANCE: These study findings suggest superior effectiveness of cenobamate over brivaracetam, lacosamide, and perampanel in adults with drug-resistant focal epilepsy in a large real-world setting.
引用
- Cerulli Irelli E, Roberti R, Borioni MS, et al. Comparative Effectiveness of Brivaracetam, Cenobamate, Lacosamide, and Perampanel in Focal Epilepsy. JAMA Neurol. 2026. PMID: 41661607. doi:10.1001/jamaneurol.2025.5625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。